The Technical Analyst
Graphite Bio, Inc. [GRPH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Graphite Bio, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.75% $3.18
America/New_York / 21 mar 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 185.19 mill |
| EPS: | -15.33 |
| P/E: | -0.210 |
| Earnings Date: | Mar 25, 2024 |
| SharesOutstanding: | 58.24 mill |
| Avg Daily Volume: | 0.0410 mill |
| RATING 2024-03-21 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.210 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.210 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.25 (2.31%) $0.0735 |
| Date: 2024-03-27 |
| Expected Trading Range (DAY) |
|---|
|
$ 21.11 - 23.41 ( +/- 5.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-28 | Drapkin Kimberlee C | Buy | 40 000 | Stock Option (right to buy) |
| 2023-07-28 | Drapkin Kimberlee C | Buy | 0 | |
| 2023-07-19 | Viney Joanne L. | Buy | 20 000 | Stock Option (right to buy) |
| 2023-07-19 | Porteus Matthew | Buy | 20 000 | Stock Option (right to buy) |
| 2023-07-19 | Karsen Perry A | Buy | 20 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 97 transactions |
| Buy: 36 276 632 | Sell: 68 481 989 |
Forecast:
16:00 - $22.33
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $22.33
Forecast 2: 16:00 - $22.33
Forecast 3: 16:00 - $22.33
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.18 (-2.75% ) |
| Volume | 0.299 mill |
| Avg. Vol. | 0.0410 mill |
| % of Avg. Vol | 731.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GRPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GRPH
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-08 17:00:00 - Press Release
Graphite Bio Declares Special Dividend In Connection With Proposed Merger With Lenz Therapeutics
South san francisco, calif.--(business wire)---- $grph #graphitebio--graphite bio, inc. (nasdaq: grph) (“graphite” or the “company”) today announced that its board of directors has declared a special dividend in connection with the previously announced merger (the “merger”) with lenz therapeutics, inc. (“lenz”) pursuant to the agreement and plan of merger, dated november 14, 2023 (the “merger agreement”). the special dividend, which the company estimates will be $1.03 per share of graphite's common stock, will be pay.
2024-02-27 15:31:00 - Press Release
Graphite Bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Graphite Bio, Inc. - Grph
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of graphite bio, inc. (nasdaqgm: grph) with lenz therapeutics. under the terms of the proposed transaction, graphite shareholders will end up owning approximately 35% of the combined company, subject to possible adjustment. ksf is seeking to determine whether the merger and the process that led to it are adequa.
2024-01-26 20:52:00 - Press Release
Graphite Bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Graphite Bio, Inc. - Grph
New orleans , jan. 26, 2024 /prnewswire/ -- former attorney general of louisiana charles c. foti, jr., esq.
2023-11-17 18:38:00 - Press Release
Graphite Bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Graphite Bio, Inc. - Grph
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of graphite bio, inc. (nasdaqgm: grph) with lenz therapeutics. under the terms of the proposed transaction, graphite shareholders will end up owning approximately 35% of the combined company, subject to possible adjustment. ksf is seeking to determine whether the merger and the process that led to it are adequa.
2023-11-16 14:08:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Graphite Bio, Inc. Has Obtained A Fair Price In Its Transaction With Lenz Therapeutics
Milwaukee , nov. 16, 2023 /prnewswire/ -- ademi llp is investigating graphite bio (nasdaq: grph) for possible breaches of fiduciary duty and other violations of law in its transaction with lenz therapeutics. click here to learn how to join the https://www.ademilaw.com/case/graphite-bio-inc or call guri ademi toll-free at 866-264-3995.
Latest News
2023-11-16 13:32:34 - Zacks Investment Research
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
Graphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-03-13 14:08:11 - TechXplore
Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs
About 600 more tech and biotech layoffs rocked the Bay Area job market in a fresh round of cutbacks that suggest the staffing reductions in the region have yet to run their course, new state government filings show.
2023-01-10 11:17:57 - Zacks Investment Research
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-01-10 07:33:59 - Benzinga
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2022-12-09 21:19:03 - Seeking Alpha
Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in gene therapy. I discuss why I believe GRPH is a prime candidate for the Compounding Healthcare “Bio Boom” Portfolio.
2022-10-20 10:14:21 - Investors Business Daily
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
2022-06-17 14:37:04 - Benzinga
BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock
BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors.
2022-05-03 09:33:55 - PennyStocks
Best Penny Stocks to Buy Today? 3 to Watch on May 3rd
What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-06 16:21:07 - GuruFocus
SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies
Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in the NextGen Bio “Class of 2022.
2021-11-18 04:26:59 - Seeking Alpha
Graphite Bio: An Important Stock To Track In The Gene Editing Space
